Hhlr Advisors, Ltd. Bei Gene, Ltd. Transaction History
Hhlr Advisors, Ltd.
- $3.26 Billion
- Q1 2025
A detailed history of Hhlr Advisors, Ltd. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Hhlr Advisors, Ltd. holds 1,034,306 shares of BGNE stock, worth $234 Million. This represents 7.2% of its overall portfolio holdings.
Number of Shares
1,034,306
Previous 3,804,406
72.81%
Holding current value
$234 Million
Previous $703 Million
66.63%
% of portfolio
7.2%
Previous 26.88%
Shares
5 transactions
Others Institutions Holding BGNE
# of Institutions
286Shares Held
36.2MCall Options Held
111KPut Options Held
112K-
Baker Bros. Advisors LP New York, NY8.8MShares$1.99 Billion23.78% of portfolio
-
Capital International Investors Los Angeles, CA5.09MShares$1.15 Billion0.24% of portfolio
-
Primecap Management CO Pasadena, CA5.09MShares$1.15 Billion0.94% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.71MShares$615 Million0.09% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U0994KShares$225 Million1.15% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...